Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb study assessing TV1001SR for the treatment of Peripheral Artery Disease (PAD)

Next Previous
Trial Profile

A phase IIb study assessing TV1001SR for the treatment of Peripheral Artery Disease (PAD)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium nitrite (Primary)
  • Indications Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors JanOne

Most Recent Events

  • 04 Jan 2022 According to a JanOne media release, the company plans to begin this trial in late 2022.
  • 28 Sep 2021 According to a JanOne media release, the company announced that it is revising its development strategy based on recent communications with the U.S. Food and Drug administration (FDA) for its upcoming clinical trial of lead drug candidate JAN101 as a treatment for Peripheral Artery Disease (PAD).
  • 22 Jul 2021 According to a JanOne media release,CPC Clinical Research (CPC), a full-service academic research organization (ARO) has been selected as manager for Planning, Organization, and Day-to-Day Execution of the Trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top